CULLINAN THERAPEUTICS, INC. Revenue
CULLINAN THERAPEUTICS, INC. (CGEM) reported Revenue of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-09.
Discontinued › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2023-03-09
- CULLINAN THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2022-12-31 was $0.00.
- CULLINAN THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2022-09-30 was $0.00.
- CULLINAN THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2022-06-30 was $0.00.
- CULLINAN THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2022-03-31 was $0.00, a 100.00% decline year-over-year.
- CULLINAN THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- CULLINAN THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2021 was $18.94M.
- CULLINAN THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2020 was $0.00.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $0.00 derived: sum of 2 quarters · filed 2023-03-09 | $0.00 derived: sum of 3 quarters · filed 2023-03-09 | $0.00 10-K · filed 2023-03-09 |
| 2022-09-30 | $0.00 10-Q · filed 2022-11-14 | $0.00 derived: sum of 2 quarters · filed 2022-11-14 | $0.00 10-Q · filed 2022-11-14 | $0.00 derived: sum of 4 quarters · filed 2023-03-09 |
| 2022-06-30 | $0.00 10-Q · filed 2022-08-10 | $0.00 10-Q · filed 2022-08-10 | $0.00 derived: sum of 3 quarters · filed 2023-03-09 | $0.00 derived: sum of 4 quarters · filed 2023-03-09 |
| 2022-03-31 | $0.00 10-Q · filed 2022-05-16 | $0.00 derived: sum of 2 quarters · filed 2023-03-09 | $0.00 derived: sum of 3 quarters · filed 2023-03-09 | $0.00 derived: sum of 4 quarters · filed 2023-03-09 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $0.00 derived: sum of 2 quarters · filed 2023-03-09 | $0.00 derived: sum of 3 quarters · filed 2023-03-09 | $18.94M 10-K · filed 2023-03-09 |
| 2021-09-30 | $0.00 10-Q · filed 2022-11-14 | $0.00 derived: sum of 2 quarters · filed 2022-11-14 | $18.94M 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $0.00 10-Q · filed 2022-08-10 | $18.94M 10-Q · filed 2022-08-10 | ||
| 2021-03-31 | $18.94M 10-Q · filed 2022-05-16 | |||
| 2020-12-31 | $0.00 10-K · filed 2022-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |